SCR-8388 / Simcere - LARVOL DELTA

SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers (AACR 2023) - "Notably, SCR-8388 demonstrated synergistic effects with the anti-EGFR antibody (cetuximab) both in Kras-mutant and WT cell lines in vitro and in vivo. In summary, SCR-8388 is a highly potent and selective SOS1 inhibitor, and effectively inhibits Kras-mutant tumors as mono- or combo therapeutics."

Oncology • DLD • KRAS